Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease
Completed
Conditions studied: Polycystic Kidney Disease
In brief
Gut microbes can influence numerous aspects of human biology. Alterations in the function and composition of gut microbial flora (gut microbiota ) have been linked to inflammatory bowel disease, chronic inflammation, dyslipidemia, diabetes mellitus, atopic disorders, cardiovascular disease, neoplasms, and obesity. However, little is known whether renal failure alters the composition of gut microbiota and whether an alteration in the gut microbiota of patients with renal failure impacts on the development of co-morbid conditions such as accelerated atherosclerosis, abnormal bone mineral metabolism, and chronic inflammation that are associated with renal failure. Nonetheless, several lines of evidence suggest that renal failure alters the chemical environment of the intestinal lumen, which could impose a selective pressure on the growth of certain gut microbes. The investigators hypothesize that the gut microbiota of patients with renal failure is different from those without renal failure. To test this hypothesis the investigators are conducting a cross-sectional study of gut microbiota in patients with different degrees of renal failure due to polycystic kidney disease (PKD).
Key facts
- Study ID
- NCT02142101
- Run by
- Icahn School of Medicine at Mount Sinai
- People needed
- 18
- Starts
- 2013-12-01
- Expected to finish
- 2015-12-01
- Last updated by the study team
- 2016-01-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age > 18 years.
- Patients with PKD.
- Patients are able to understand and give consent.
You may not qualify if…
- Patient on antibiotics or vitamin supplement (except vitamin D analogs) in the last three months.
- Advanced liver disease, advanced cardiovascular disease, heart failure with EF < 30%, and autoimmune disease.
- The use of chemotherapy, antibiotics, immunosuppressive medications, probiotics, and steroid in the last three month.
- Intravenous or oral iron supplementation, laxatives, and kayexalate in the last month.
- History of intra abdominal surgery, small or large intestine resection or small bowel obstruction.
- History of colon cancer or gastrointestinal bleed.
Where it is running
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.